Page last updated: 2024-11-05

propantheline bromide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Propantheline bromide is a synthetic anticholinergic drug that acts as a competitive antagonist of acetylcholine at muscarinic receptors. It was first synthesized in the 1950s and is used to treat a variety of conditions, including peptic ulcers, irritable bowel syndrome, and urinary incontinence. The drug is typically administered orally. Propantheline bromide works by blocking the action of acetylcholine, a neurotransmitter that is responsible for stimulating smooth muscle contraction and glandular secretions. By blocking acetylcholine, propantheline bromide can reduce muscle spasms, decrease gastric acid production, and slow the emptying of the stomach. The drug is generally well-tolerated, but common side effects include dry mouth, blurred vision, constipation, and urinary retention. The drug is typically not used in patients with glaucoma, myasthenia gravis, or urinary retention. Propantheline bromide is often studied as a potential treatment for various conditions, including inflammatory bowel disease, Parkinson's disease, and Alzheimer's disease. The drug has also been investigated as a possible treatment for cancer, but further research is needed to determine its efficacy. '
```

Cross-References

ID SourceID
PubMed CID9279
CHEMBL ID1240
CHEBI ID8482
SCHEMBL ID40291
MeSH IDM0351182

Synonyms (144)

Synonym
AC-13428
MLS001333690
MLS001076547
smr000058661
n-methyl-n-(1-methylethyl)-n-{2-[(9h-xanthen-9-ylcarbonyl)oxy]ethyl}propan-2-aminium bromide
EU-0101014
propantheline bromide, >=97% (tlc), powder
PRESTWICK_241
propantheline bromide
50-34-0
ercotina
einecs 200-030-6
diisopropyl(2-hydroxyethyl)methylammonium bromide xanthene-9-carboxylate
(2-hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate
pantas
ketaman
sc-3171
probantine
pantheline
ccris 6271
neopepulsan
prodixamon
neometantyl
2-propanaminium, n-methyl-n-(1-methylethyl)-n-(2-((9h-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide
kivatin
ercorax
pro-gastron
nci-c56257
pervagal
bromuro de proantelina [inn-spanish]
propantel
bromure de propantheline [inn-french]
propanthelini bromidum [inn-latin]
corrigast
ammonium, diisopropyl(2-hydroxyethyl)methyl-, bromide, xanthene-9-carboxylate
xanthene-9-carboxylic acid, ester with (2-hydroxyethyl)diisopropylmethylammonium bromide
propantheline bromide (jp17/usp/inn)
D00481 ,
NCGC00094306-03
NCGC00094306-02
pro-banthine
MLS000028703 ,
SPECTRUM1500511
NCGC00094306-05
NCGC00094306-01
NCGC00094306-04
P 8891 ,
(2-hydroxyethyl)diisopropylmethylammonium bromide xanthene-9-carboxylate bromide
HMS2092C19
nsc-757294
CHEMBL1240
HMS502I04
HMS1570F15
HMS1920L18
HMS3259E04
HMS3263K09
HMS2097F15
bromide, propantheline
NCGC00255145-01
tox21_302331
dtxcid203519
dtxsid2023519 ,
methyl-di(propan-2-yl)-[2-(9h-xanthen-9-ylcarbonyloxy)ethyl]azanium bromide
methyl-[2-[oxo(9h-xanthen-9-yl)methoxy]ethyl]-di(propan-2-yl)ammonium bromide
A828073
pharmakon1600-01500511
nsc757294
tox21_111265
HMS2234M23
CCG-39238
bromuro de proantelina
bromure de propantheline
propantelina bromuro
nsc 757294
unii-ux9z118x9f
propanthelini bromidum
propantheline bromide [usp:inn:ban:jan]
2-propanaminium, n-methyl-n-(1-methylethyl)-n-(2-((9h-xanthen-9-ylcarbonyl)oxy)ethyl)-, bromide (1:1)
ux9z118x9f ,
FT-0603218
LP01014
AKOS015895527
HMS3370N21
propantheline bromide [jan]
propantheline bromide [who-dd]
propantheline bromide [orange book]
propantheline bromide [usp-rs]
propantheline bromide [mi]
propantheline bromide [usp impurity]
n-isopropyl-n-methyl-n-(2-((9h-xanthen-9-ylcarbonyl)oxy)ethyl)propan-2-aminium bromide
propantheline bromide [mart.]
propantheline bromide [inn]
propantheline bromide [ep impurity]
propantheline bromide [usp monograph]
NC00529
SCHEMBL40291
tox21_111265_1
NCGC00015854-10
KS-1386
CS-4797
NCGC00261699-01
tox21_501014
REGID_FOR_CID_9279
W-105970
HY-B1188
propantheline (bromide)
OPERA_ID_1667
mfcd00050291
SR-01000003171-2
sr-01000003171
propantheline bromide, united states pharmacopeia (usp) reference standard
propantheline bromide, pharmaceutical secondary standard; certified reference material
CHEBI:8482
SR-01000003171-7
SR-01000003171-4
HMS3714F15
2-propanaminium,n-methyl-n-(1-methylethyl)-n-[2-[(9h-xanthen-9-ylcarbonyl)oxy]ethyl]-,bromide
n-(2-(9h-xanthene-9-carbonyloxy)ethyl)-n-isopropyl-n-methylpropan-2-aminium bromide
propantheline,(s)
HMS3886K03
Q27291318
D82053
ammonium, (2-hydroxyethyl)diisopropylmethyl-, bromide, xanthene-9-carboxylate
propanthelini bromidum (inn-latin)
propantheline bromide (usp monograph)
n-methyl-n,n-bis(1-methylethyl)-2-((9h-xanthen-9-ylcarbonyl)oxy)ethylaminium bromide
pro-banthine bromide
propantheline bromide (mart.)
bromuro de proantelina (inn-spanish)
propanthalinium (cation)
propanthline
a03ab05
propantheline bromide (usp impurity)
sc 3171
beta-diisopropylaminoethyl xanthene-9-carboxylate methobromide
propantheline bromide (ep impurity)
propantheline bromide (usp:inn:ban:jan)
bromure de propantheline (inn-french)
bromuro de propantelina
propanthelinii bromidum
xanthene-9-carboxylic acid, ester with (2-hydroxyethyl)diisopropylmethyl-ammonium bromide
propantheline bromide (usp-rs)
beta-diisopropylaminoethyl 9-xanthenecarboxylate methobromide
propanthelinium bromatum

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
xanthenes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency24.36160.003245.467312,589.2998AID1705; AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency70.79460.004023.8416100.0000AID485290
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency0.25120.125919.1169125.8920AID2549
acetylcholinesteraseHomo sapiens (human)Potency35.79010.002541.796015,848.9004AID1347395; AID1347398
thioredoxin reductaseRattus norvegicus (Norway rat)Potency0.79430.100020.879379.4328AID588453
RAR-related orphan receptor gammaMus musculus (house mouse)Potency29.84930.006038.004119,952.5996AID1159521
GLI family zinc finger 3Homo sapiens (human)Potency6.85900.000714.592883.7951AID1259369
Microtubule-associated protein tauHomo sapiens (human)Potency26.20000.180013.557439.8107AID1460; AID1468
AR proteinHomo sapiens (human)Potency57.80670.000221.22318,912.5098AID1259243; AID1259247; AID743042; AID743054
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency22.38380.001022.650876.6163AID1224893
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.49150.001530.607315,848.9004AID1224821
pregnane X nuclear receptorHomo sapiens (human)Potency7.69590.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency6.00120.000229.305416,493.5996AID743075
cytochrome P450 2D6Homo sapiens (human)Potency0.30900.00108.379861.1304AID1645840
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency41.26820.001019.414170.9645AID743094; AID743140
IDH1Homo sapiens (human)Potency29.09290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02240.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency24.33650.000723.06741,258.9301AID743085
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency42.561523.934123.934123.9341AID1967
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency4.89220.00419.984825.9290AID504444; AID720524
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency19.95260.01789.637444.6684AID588834
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency11.22020.794321.275750.1187AID624246
importin subunit beta-1 isoform 1Homo sapiens (human)Potency20.59625.804836.130665.1308AID540253
snurportin-1Homo sapiens (human)Potency20.59625.804836.130665.1308AID540253
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency20.59625.804816.996225.9290AID540253
survival motor neuron protein isoform dHomo sapiens (human)Potency0.89130.125912.234435.4813AID1458
lamin isoform A-delta10Homo sapiens (human)Potency12.77970.891312.067628.1838AID1459; AID1487
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency3.16231.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)291.30000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
short transient receptor potential channel 6 isoform 1Mus musculus (house mouse)EC50 (µMol)0.07000.020020.518970.7900AID2696
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (12)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (105)

Assay IDTitleYearJournalArticle
AID1851788Stability in CD-1 mouse whole blood assessed as compound remaining at 2 uM and measured at 120 mins LC-MS/MS analysis2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and antibacterial activity of derivatives of Tryptophanyl-tRNA synthetase inhibitor indolmycin.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID106806Inhibition of malate dehydrogenase (MDH) at 400 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID43581Inhibition of beta-lactamase at 100 uM2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1355805Stability of the compound in human plasma assessed as compound remaining at 100 uM measured after 120 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1692516Stability of the compound in human plasma assessed as parent compound remaining measured after 30 mins by LC-MS/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
AID1736745Metabolic stability in human plasma assessed as parent compound remaining after 30 mins by LC/MS/MS method2020European journal of medicinal chemistry, Mar-15, Volume: 190Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities.
AID1519608Stability in human plasma assessed as compound remaining incubated for 0 mins by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1355804Stability of the compound in human plasma assessed as compound remaining at 100 uM measured after 60 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1409433Half life in human plasma at 2 uM by LC/MS/MS analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1736744Metabolic stability in human plasma assessed as parent compound remaining after 10 mins by LC/MS/MS method2020European journal of medicinal chemistry, Mar-15, Volume: 190Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities.
AID1519606Stability in human plasma assessed as compound remaining incubated for 10 mins by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1409429Metabolic stability in human plasma assessed as compound remaining at 2 uM measured after 10 mins by LC/MS/MS analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID1355802Stability of the compound in human plasma assessed as compound remaining at 100 uM measured after 10 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1519607Stability in human plasma assessed as compound remaining incubated for 30 mins by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
AID1692515Stability of the compound in human plasma assessed as parent compound remaining measured after 10 mins by LC-MS/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
AID1519604Stability in human plasma assessed as compound remaining incubated for 120 mins by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1851786Stability in CD-1 mouse whole blood assessed as compound remaining at 2 uM and measured at 30 mins LC-MS/MS analysis2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and antibacterial activity of derivatives of Tryptophanyl-tRNA synthetase inhibitor indolmycin.
AID1519605Stability in human plasma assessed as compound remaining incubated for 60 mins by LC-MS/MS analysis2020European journal of medicinal chemistry, Jan-01, Volume: 185Design, synthesis and biological evaluation of oseltamivir derivatives containing pyridyl group as potent inhibitors of neuraminidase for influenza A.
AID1692518Stability of the compound in human plasma assessed as parent compound remaining measured after 120 mins by LC-MS/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
AID1851787Stability in CD-1 mouse whole blood assessed as compound remaining at 2 uM and measured at 60 mins LC-MS/MS analysis2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and antibacterial activity of derivatives of Tryptophanyl-tRNA synthetase inhibitor indolmycin.
AID1851785Stability in CD-1 mouse whole blood assessed as compound remaining at 2 uM and measured at 10 mins LC-MS/MS analysis2022European journal of medicinal chemistry, Nov-05, Volume: 241Design, synthesis, and antibacterial activity of derivatives of Tryptophanyl-tRNA synthetase inhibitor indolmycin.
AID1355803Stability of the compound in human plasma assessed as compound remaining at 100 uM measured after 30 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID1692514Stability of the compound in human plasma assessed as parent compound remaining by LC-MS/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
AID1355801Stability of the compound in human plasma assessed as compound remaining at 100 uM measured immediately by LC-MS/MS analysis2018Journal of medicinal chemistry, Jul-26, Volume: 61, Issue:14
Optimization of N-Substituted Oseltamivir Derivatives as Potent Inhibitors of Group-1 and -2 Influenza A Neuraminidases, Including a Drug-Resistant Variant.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1409431Metabolic stability in human plasma assessed as compound remaining at 2 uM measured after 60 mins by LC/MS/MS analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID1409430Metabolic stability in human plasma assessed as compound remaining at 2 uM measured after 30 mins by LC/MS/MS analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID1617359Stability in human plasma assessed as compound remaining at 10 uM measured up to 60 mins by LC-ESI-MS/MS analysis2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Development of Robust 17(
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID52791Compound was tested for the inhibition of Chymotrypsinogen at 250 uM (Inhibition is time dependent)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1736747Metabolic stability in human plasma assessed as parent compound remaining after 120 mins by LC/MS/MS method2020European journal of medicinal chemistry, Mar-15, Volume: 190Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities.
AID1548580Stability in human plasma assessed as compound remaining level at 2 uM incubated for 120 mins at 37 degC by LC-MS/MS analysis2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Design, Synthesis, and Mechanism Study of Benzenesulfonamide-Containing Phenylalanine Derivatives as Novel HIV-1 Capsid Inhibitors with Improved Antiviral Activities.
AID1409432Metabolic stability in human plasma assessed as compound remaining at 2 uM measured after 120 mins by LC/MS/MS analysis2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Structure-Based Optimization of N-Substituted Oseltamivir Derivatives as Potent Anti-Influenza A Virus Agents with Significantly Improved Potency against Oseltamivir-Resistant N1-H274Y Variant.
AID1692517Stability of the compound in human plasma assessed as parent compound remaining measured after 60 mins by LC-MS/MS analysis2020European journal of medicinal chemistry, Aug-15, Volume: 200Discovery of a non-zwitterionic oseltamivir analogue as a potent influenza a neuraminidase inhibitor.
AID1736746Metabolic stability in human plasma assessed as parent compound remaining after 60 mins by LC/MS/MS method2020European journal of medicinal chemistry, Mar-15, Volume: 190Design, synthesis and structure-activity relationships of 4-phenyl-1H-1,2,3-triazole phenylalanine derivatives as novel HIV-1 capsid inhibitors with promising antiviral activities.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (34)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (14.71)29.6817
2010's17 (50.00)24.3611
2020's12 (35.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.61

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.61 (24.57)
Research Supply Index3.56 (2.92)
Research Growth Index4.82 (4.65)
Search Engine Demand Index111.71 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (67.61)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (2.94%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other33 (97.06%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]